{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Inconduite professionnelle : Questions médicales les plus fréquentes",
"headline": "Inconduite professionnelle : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Inconduite professionnelle : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-17",
"dateModified": "2025-03-14",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Inconduite professionnelle"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Éthique",
"url": "https://questionsmedicales.fr/mesh/D004989",
"about": {
"@type": "MedicalCondition",
"name": "Éthique",
"code": {
"@type": "MedicalCode",
"code": "D004989",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "N05.350"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Inconduite scientifique",
"alternateName": "Scientific Misconduct",
"url": "https://questionsmedicales.fr/mesh/D015871",
"about": {
"@type": "MedicalCondition",
"name": "Inconduite scientifique",
"code": {
"@type": "MedicalCode",
"code": "D015871",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "N05.350.979.500"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Inconduite professionnelle",
"alternateName": "Professional Misconduct",
"code": {
"@type": "MedicalCode",
"code": "D028743",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Charles Piller",
"url": "https://questionsmedicales.fr/author/Charles%20Piller",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Shokoh Varaei",
"url": "https://questionsmedicales.fr/author/Shokoh%20Varaei",
"affiliation": {
"@type": "Organization",
"name": "School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran."
}
},
{
"@type": "Person",
"name": "Nahid Dehghan Nayeri",
"url": "https://questionsmedicales.fr/author/Nahid%20Dehghan%20Nayeri",
"affiliation": {
"@type": "Organization",
"name": "Nursing and Midwifery Care Research Center, School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran."
}
},
{
"@type": "Person",
"name": "Leila Sayadi",
"url": "https://questionsmedicales.fr/author/Leila%20Sayadi",
"affiliation": {
"@type": "Organization",
"name": "School of nursing & midwifery, Nursing and Midwifery Care Research Center, Tehran University of Medical Sciences, Tehran, Iran."
}
},
{
"@type": "Person",
"name": "Akram Ghobadi",
"url": "https://questionsmedicales.fr/author/Akram%20Ghobadi",
"affiliation": {
"@type": "Organization",
"name": "School of Nursing and Midwifery, Kermanshah University of Medical Sciences, Kermanshah, Iran. ghobadi_a57@yahoo.com."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Anti-Neutrophil Extracellular Trap Antibodies in Antiphospholipid Antibody-Positive Patients: Results From the Antiphospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking Clinical Database and Repository.",
"datePublished": "2023-05-18",
"url": "https://questionsmedicales.fr/article/36862141",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/art.42489"
}
},
{
"@type": "ScholarlyArticle",
"name": "Impact of sodium-glucose cotransporter-2 inhibitors on the risk of hip fracture in older patients in Japan using a nationwide administrative claims database: A matched case-control study.",
"datePublished": "2023-05-04",
"url": "https://questionsmedicales.fr/article/37139826",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/ggi.14591"
}
},
{
"@type": "ScholarlyArticle",
"name": "Risk Factors and 120-Day Functional Outcomes of Delirium After Hip Fracture Surgery: A Prospective Cohort Study Using the UK National Hip Fracture Database (NHFD).",
"datePublished": "2023-03-15",
"url": "https://questionsmedicales.fr/article/36933569",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jamda.2023.02.008"
}
},
{
"@type": "ScholarlyArticle",
"name": "Mortality analysis among sepsis patients in and out of intensive care units using the Japanese nationwide medical claims database: a study by the Japan Sepsis Alliance study group.",
"datePublished": "2023-01-07",
"url": "https://questionsmedicales.fr/article/36611188",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s40560-023-00650-x"
}
},
{
"@type": "ScholarlyArticle",
"name": "Clinical impact of lipid injectable emulsion in internal medicine inpatients exclusively receiving parenteral nutrition: a propensity score matching analysis from a Japanese medical claims database.",
"datePublished": "2022-10-27",
"url": "https://questionsmedicales.fr/article/36289527",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12916-022-02568-x"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Qualité, accès, évaluation des soins de santé",
"item": "https://questionsmedicales.fr/mesh/D017530"
},
{
"@type": "ListItem",
"position": 3,
"name": "Éthique",
"item": "https://questionsmedicales.fr/mesh/D004989"
},
{
"@type": "ListItem",
"position": 4,
"name": "Inconduite professionnelle",
"item": "https://questionsmedicales.fr/mesh/D028743"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Inconduite professionnelle - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Inconduite professionnelle",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-02",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Inconduite professionnelle",
"description": "Comment identifier l'inconduite professionnelle ?\nQuels signes indiquent une inconduite ?\nQui peut signaler une inconduite ?\nQuels outils aident au diagnostic ?\nQuelles sont les conséquences d'un diagnostic tardif ?",
"url": "https://questionsmedicales.fr/mesh/D028743?mesh_terms=Databases,+Factual&page=1000#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Inconduite professionnelle",
"description": "Quels symptômes peuvent alerter sur une inconduite ?\nComment les patients réagissent-ils à l'inconduite ?\nQuels effets psychologiques l'inconduite a-t-elle ?\nY a-t-il des signes de stress chez le professionnel ?\nComment l'inconduite affecte-t-elle l'équipe médicale ?",
"url": "https://questionsmedicales.fr/mesh/D028743?mesh_terms=Databases,+Factual&page=1000#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Inconduite professionnelle",
"description": "Comment prévenir l'inconduite professionnelle ?\nQuel rôle joue la supervision dans la prévention ?\nComment impliquer les patients dans la prévention ?\nQuels outils technologiques aident à la prévention ?\nQuelle est l'importance de la culture organisationnelle ?",
"url": "https://questionsmedicales.fr/mesh/D028743?mesh_terms=Databases,+Factual&page=1000#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Inconduite professionnelle",
"description": "Quels traitements pour les victimes d'inconduite ?\nComment traiter l'inconduite chez un professionnel ?\nQuelles sanctions pour inconduite professionnelle ?\nComment réhabiliter un professionnel fautif ?\nQuels programmes de prévention existent ?",
"url": "https://questionsmedicales.fr/mesh/D028743?mesh_terms=Databases,+Factual&page=1000#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Inconduite professionnelle",
"description": "Quelles complications peuvent résulter de l'inconduite ?\nComment l'inconduite affecte-t-elle la réputation ?\nY a-t-il des conséquences légales ?\nComment l'inconduite impacte-t-elle le personnel ?\nQuelles sont les répercussions sur les patients ?",
"url": "https://questionsmedicales.fr/mesh/D028743?mesh_terms=Databases,+Factual&page=1000#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Inconduite professionnelle",
"description": "Quels facteurs augmentent le risque d'inconduite ?\nComment la formation influence-t-elle le risque ?\nQuel rôle joue l'environnement de travail ?\nLes antécédents personnels influencent-ils le risque ?\nComment la culture institutionnelle impacte-t-elle le risque ?",
"url": "https://questionsmedicales.fr/mesh/D028743?mesh_terms=Databases,+Factual&page=1000#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier l'inconduite professionnelle ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'inconduite se détecte par des plaintes, des comportements inappropriés ou des violations éthiques."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une inconduite ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des comportements tels que négligence, abus de pouvoir ou fraude peuvent indiquer une inconduite."
}
},
{
"@type": "Question",
"name": "Qui peut signaler une inconduite ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Tout membre du personnel médical, patient ou tiers peut signaler une inconduite professionnelle."
}
},
{
"@type": "Question",
"name": "Quels outils aident au diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des enquêtes, des audits et des évaluations de performance aident à diagnostiquer l'inconduite."
}
},
{
"@type": "Question",
"name": "Quelles sont les conséquences d'un diagnostic tardif ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic tardif peut aggraver les dommages aux patients et compromettre la sécurité des soins."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent alerter sur une inconduite ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des plaintes répétées de patients, des erreurs fréquentes ou un comportement inapproprié sont des symptômes."
}
},
{
"@type": "Question",
"name": "Comment les patients réagissent-ils à l'inconduite ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients peuvent ressentir de la méfiance, de l'anxiété ou de la détresse face à l'inconduite."
}
},
{
"@type": "Question",
"name": "Quels effets psychologiques l'inconduite a-t-elle ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'inconduite peut entraîner des traumatismes psychologiques chez les patients affectés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes de stress chez le professionnel ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un professionnel en inconduite peut montrer des signes de stress, d'irritabilité ou d'isolement."
}
},
{
"@type": "Question",
"name": "Comment l'inconduite affecte-t-elle l'équipe médicale ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut créer des tensions, diminuer la confiance et affecter la collaboration au sein de l'équipe."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'inconduite professionnelle ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par des formations éthiques, des codes de conduite et un environnement de travail sain."
}
},
{
"@type": "Question",
"name": "Quel rôle joue la supervision dans la prévention ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une supervision adéquate permet de détecter et de corriger les comportements inappropriés rapidement."
}
},
{
"@type": "Question",
"name": "Comment impliquer les patients dans la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients peuvent être formés à reconnaître et signaler des comportements inappropriés."
}
},
{
"@type": "Question",
"name": "Quels outils technologiques aident à la prévention ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des systèmes de signalement en ligne et des applications de suivi des comportements peuvent aider."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance de la culture organisationnelle ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une culture organisationnelle positive favorise l'éthique et réduit les risques d'inconduite."
}
},
{
"@type": "Question",
"name": "Quels traitements pour les victimes d'inconduite ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les victimes peuvent bénéficier de thérapies psychologiques et de soutien émotionnel."
}
},
{
"@type": "Question",
"name": "Comment traiter l'inconduite chez un professionnel ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des mesures disciplinaires, des formations et un suivi psychologique peuvent être nécessaires."
}
},
{
"@type": "Question",
"name": "Quelles sanctions pour inconduite professionnelle ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les sanctions peuvent inclure des avertissements, des suspensions ou des radiations de l'ordre."
}
},
{
"@type": "Question",
"name": "Comment réhabiliter un professionnel fautif ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La réhabilitation peut passer par des formations, du mentorat et un suivi régulier."
}
},
{
"@type": "Question",
"name": "Quels programmes de prévention existent ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des programmes de formation éthique et de sensibilisation sont mis en place pour prévenir l'inconduite."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent résulter de l'inconduite ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des dommages physiques, psychologiques et une perte de confiance dans le système de santé."
}
},
{
"@type": "Question",
"name": "Comment l'inconduite affecte-t-elle la réputation ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'inconduite peut gravement nuire à la réputation du professionnel et de l'établissement de santé."
}
},
{
"@type": "Question",
"name": "Y a-t-il des conséquences légales ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'inconduite peut entraîner des poursuites judiciaires et des sanctions pénales."
}
},
{
"@type": "Question",
"name": "Comment l'inconduite impacte-t-elle le personnel ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut créer un environnement de travail toxique, affectant le moral et la productivité du personnel."
}
},
{
"@type": "Question",
"name": "Quelles sont les répercussions sur les patients ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients peuvent subir des erreurs médicales, des abus ou une détérioration de leur état de santé."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque d'inconduite ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress, la surcharge de travail et un manque de supervision sont des facteurs de risque importants."
}
},
{
"@type": "Question",
"name": "Comment la formation influence-t-elle le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une formation insuffisante peut accroître le risque d'inconduite en diminuant la sensibilisation éthique."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'environnement de travail ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un environnement de travail toxique ou compétitif peut favoriser l'inconduite professionnelle."
}
},
{
"@type": "Question",
"name": "Les antécédents personnels influencent-ils le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de comportements inappropriés ou de problèmes psychologiques peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Comment la culture institutionnelle impacte-t-elle le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une culture institutionnelle laxiste envers l'éthique peut accroître le risque d'inconduite."
}
}
]
}
]
}
This study aimed to elucidate the presence, antigen specificities, and potential clinical associations of anti-neutrophil extracellular trap (anti-NET) antibodies in a multinational cohort of antiphos...
Anti-NET IgG/IgM levels were measured in serum samples from 389 aPL-positive patients; 308 patients met the classification criteria for antiphospholipid syndrome. Multivariate logistic regression with...
We found elevated levels of anti-NET IgG and/or IgM in 45% of the aPL-positive patients. High anti-NET antibody levels are associated with more circulating myeloperoxidase (MPO)-DNA complexes, which a...
These data reveal high levels of anti-NET antibodies in 45% of aPL-positive patients, where they potentially activate the complement cascade. While anti-NET IgM may especially recognize DNA in NETs, a...
Some clinical trials have shown that sodium-glucose cotransporter-2 (SGLT2) inhibitors are associated with fracture risk. However, this notion remains controversial. This study aimed to evaluate hip f...
Using large-scale real-world data, this case-control study investigated hospitalized patients between January 2018 and December 2020. Patients were aged 65-89 years and had been prescribed with SGLT2 ...
After matching, 396 cases and 1081 controls were identified. The adjusted odds ratio for patients receiving treatment with SGLT2 inhibitors was 0.83 (95% confidence interval: 0.55-1.26), indicating no...
Our study showed that SGLT2 inhibitors do not increase hip fractures in older patients. However, because the risk assessment of SGLT2 inhibitors by component and their concomitant use with other antid...
To identify risk factors of postoperative delirium among hip fracture patients with normal preoperative cognition, and examine associations with returning home or recovery of mobility....
Prospective cohort study....
We used the National Hip Fracture Database (NHFD) to identify patients presenting with hip fracture in England (2018-2019), but excluded those with abnormal cognition [abbreviated mental test score (A...
We examined the results of routine delirium screening performed using the 4 A's Test (4AT), to assess alertness, attention, acute change, and orientation in a 4-item mental test. Associations between ...
Overall, 63,502 patients (63%) had a preoperative AMTS ≥8, in whom a postoperative 4AT score ≥4 suggestive of delirium was seen in 4454 (7%). These patients were less likely to return home [odds ratio...
Delirium after hip fracture surgery significantly reduces the likelihood of returning home or to outdoor mobility. Our findings underline the importance of measures to prevent postoperative delirium, ...
A substantial number of sepsis patients require specialized care, including multidisciplinary care, close monitoring, and artificial organ support in the intensive care unit (ICU). However, the effica...
We conducted a retrospective study using the nationwide medical claims database of sepsis patients in Japan from 2010 to 2017 with propensity score matching to adjust for baseline imbalances. Patients...
Among 1,167,901 sepsis patients (974,289 in non-ICU and 193,612 in ICU settings), the unadjusted in-hospital mortality was 22.5% among non-ICU patients and 26.2% among ICU patients (3.7% [95% CI 3.5-3...
Herein, using the nationwide medical claims database, we demonstrated that ICU admission was potentially associated with decreasing in-hospital mortality among sepsis patients. Further investigations ...
Although guidelines recommend lipid injectable emulsions (ILEs) be used as a part of parenteral nutrition, many patients in Japan receive lipid-free parenteral nutrition. Furthermore, little is known ...
A propensity score matching (PSM) analysis was performed using a medical claims database covering 451 hospitals in Japan. Participants included the following internal medicine inpatients, ages ≥ 18 ye...
After PSM, 19,602 matched pairs were formed out of 61,437 patients. The ILE group had significantly lower incidences than the non-ILE group of in-hospital mortality (20.3% vs. 26.9%; odds ratio [OR], ...
ILE use was associated with improved clinical outcomes, including lower in-hospital mortality, in internal medicine inpatients receiving parenteral nutrition....
Chronic obstructive pulmonary disease (COPD) is a condition with a relevant clinical and economic burden. Only 10% to 40% of COPD patients reporting a regular use of respiratory medications, including...
The relationship between vitamin D status and mortality in patients with osteoarthritis (OA) is unknown. This study investigated the associations of serum 25-hydroxyvitamin D [25(OH)D] concentrations ...
This study included 2556 adults with OA from the National Health and Nutrition Examination Survey (2001-2014). Death outcomes were ascertained by linkage to National Death Index (NDI) records through ...
During 16,606 person-years of follow-up, 438 all-cause deaths occurred, including 74 cardiovascular disease (CVD)-related and 78 cancer deaths. After multivariable adjustment, lower serum 25(OH)D leve...
Nonlinear associations of serum 25(OH)D levels with all-cause and CVD mortality were observed in American patients with OA. The thresholds of 27.70 and 54.40 nmol/L for CVD and all-cause mortality, re...
Polycyclic aromatic hydrocarbons (PAHs) derivatives such as oxygenated PAHs (oPAHs) and nitrated PAHs (nPAHs), are receiving raising concerns due to their high toxic potential. Incomplete solid fuel c...
To assess whether there is an association between extended in vitro culture based on embryo developmental stage at transfer and pre-malignant gestational trophoblastic disease (GTD) risk of molar preg...
A retrospective study was carried out using Human Fertilization and Embryology Authority (HFEA) anonymized register from 1999 to 2016. A total of 540,376 cycles were eligible to be included in the stu...
The prevalence of a molar pregnancy GTD among the study population was 3.4/10,000 livebirths (53/156,683) with a higher risk in the over 40 age category. No significant difference of pre-malignant GTD...
No significant association between pre-malignant molar gestational trophoblastic disease and extended in vitro embryo culture was found after analyzing 540,376 cycles of IVF and ICSI....
Scientific insights gained from the severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS) outbreaks have been assisting scientists and researchers in the quest of antivi...
The online version contains supplementary material available at 10.1007/s11224-022-01991-3....